LYNPARZA approved in the EU as adjuvant treatment for early breast cancer

First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients

PIB: Quality control of Ayush drugs

PIB: Pharmaceutical industry in Maharashtra

The total financial outlay of the scheme is Rs.500 crore for a period of five years from 2021-22 to 2025-26.

Statement from Krsnaa Diagnostics on IT survey

The news report stating Krsnaa Diagnostics has accepted Rs 100 crores of undisclosed income is incorrect and baseless.

Tealium launches customer data platform for pharma

Tealium for Pharma utilizes deep integration technology and partnerships to deliver an enhanced customer journey in one of healthcare's most vital sectors

Nuance Pharma announces the completion of dosing for all NTM-001 Phase 1 clinical study

The NTM-001 Phase I clinical study is expected to be completed by the end of 2022

AstraZeneca collaborates with – Indian Society of Nephrology to launch CKD Academy

AstraZeneca and Indian Society of Nephrology aim to help clinicians and healthcare practitioners to provide holistic kidney care to their patients.

SMS Pharmaceuticals receives approval for Ibuprofen by EDQM

With this, the company can start selling Ibuprofen in the European markets.

Lupin Diagnostics launches its first reference laboratory in Ranchi

Lupin Diagnostics will equip doctors with accurate diagnosis in the patient journey by leveraging innovative technologies

Glenmark Pharma and SaNOtize announce Peer Reviewed Publication of its Phase 3 Clinical Trials on SaNOtize's Novel Nitric Oxide Nasal Spray

The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of treatment.